USP8 Is a Novel Target for Overcoming Gefitinib Resistance in Lung Cancer

Abstract

Our results show for the first time that the inhibition of USP8 activity or reduction in USP8 expression can selectively kill NSCLC cells. We propose USP8 as a potential therapeutic target for gefitinib-resistant and -sensitive NSCLC cells.